top of page

NeuroDerm starts phase III trial of NDO612L in Parkinson's disease

Clinical stage pharmaceutical firm NeuroDerm has started a phase III clinical trial, evaluating NDO612L for the treatment of Parkinson's disease (PD).

Click on this link for more information.

source: http://clinicaltrials.pharmaceutical-business-review.com/news/neuroderm-starts-phase-iii-trial-of-ndo612l-in-parkinsons-disease-290816-4990653

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page